Genelux (GNLX) Competitors $3.07 +0.23 (+8.10%) As of 07/3/2025 03:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNLX vs. ATYR, KMDA, ATAI, TRML, MREO, RGNX, PGEN, RAPP, ORKA, and PRTCShould you be buying Genelux stock or one of its competitors? The main competitors of Genelux include aTyr Pharma (ATYR), Kamada (KMDA), atai Life Sciences (ATAI), Tourmaline Bio (TRML), Mereo BioPharma Group (MREO), REGENXBIO (RGNX), Precigen (PGEN), Rapport Therapeutics (RAPP), Oruka Therapeutics (ORKA), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical products" industry. Genelux vs. Its Competitors aTyr Pharma Kamada atai Life Sciences Tourmaline Bio Mereo BioPharma Group REGENXBIO Precigen Rapport Therapeutics Oruka Therapeutics PureTech Health aTyr Pharma (NASDAQ:ATYR) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation. Is ATYR or GNLX more profitable? aTyr Pharma's return on equity of -87.09% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets aTyr PharmaN/A -87.09% -64.77% Genelux N/A -93.04%-74.17% Which has better earnings and valuation, ATYR or GNLX? Genelux has lower revenue, but higher earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioaTyr Pharma$230K2,033.07-$64.02M-$0.81-6.49Genelux$10K11,246.52-$29.87M-$0.88-3.39 Do institutionals and insiders believe in ATYR or GNLX? 61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 3.7% of aTyr Pharma shares are held by insiders. Comparatively, 9.3% of Genelux shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer ATYR or GNLX? In the previous week, aTyr Pharma had 1 more articles in the media than Genelux. MarketBeat recorded 4 mentions for aTyr Pharma and 3 mentions for Genelux. aTyr Pharma's average media sentiment score of 0.66 beat Genelux's score of 0.39 indicating that aTyr Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genelux 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, ATYR or GNLX? aTyr Pharma has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Genelux has a beta of -0.34, suggesting that its share price is 134% less volatile than the S&P 500. Do analysts prefer ATYR or GNLX? aTyr Pharma presently has a consensus target price of $20.20, indicating a potential upside of 284.47%. Genelux has a consensus target price of $17.75, indicating a potential upside of 495.64%. Given Genelux's stronger consensus rating and higher probable upside, analysts clearly believe Genelux is more favorable than aTyr Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryaTyr Pharma beats Genelux on 9 of the 15 factors compared between the two stocks. Get Genelux News Delivered to You Automatically Sign up to receive the latest news and ratings for GNLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNLX vs. The Competition Export to ExcelMetricGeneluxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$112.45M$2.91B$5.53B$9.05BDividend YieldN/A2.44%5.24%4.03%P/E Ratio-3.3921.5627.5220.22Price / Sales11,246.52281.76421.02118.64Price / CashN/A42.7336.8958.07Price / Book3.927.518.045.67Net Income-$29.87M-$55.05M$3.18B$249.13M7 Day Performance-0.33%4.61%2.90%3.28%1 Month Performance17.79%4.72%3.70%5.55%1 Year Performance50.51%5.92%36.15%21.12% Genelux Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNLXGenelux1.7529 of 5 stars$2.98+4.9%$17.75+495.6%+55.2%$112.45M$10K-3.3910ATYRaTyr Pharma2.9814 of 5 stars$5.07+0.8%$20.20+298.4%N/A$447.69M$230K-6.2653Gap UpHigh Trading VolumeKMDAKamada4.052 of 5 stars$7.75+0.5%$14.67+89.2%+50.6%$443.36M$160.95M26.72360News CoverageATAIatai Life Sciences3.0005 of 5 stars$2.19-0.5%$8.67+295.7%+116.8%$440.74M$310K-2.4180Analyst ForecastOptions VolumeTRMLTourmaline Bio2.1424 of 5 stars$15.99-3.3%$49.33+208.5%+30.7%$424.84MN/A-4.9844MREOMereo BioPharma Group1.9697 of 5 stars$2.71+1.9%$7.60+180.4%-19.9%$422.94M$10M-38.7140RGNXREGENXBIO4.5283 of 5 stars$8.21-2.1%$31.63+285.2%-19.3%$420.85M$83.33M-2.64370Positive NewsPGENPrecigen3.7144 of 5 stars$1.42flat$6.00+322.5%+10.5%$419.16M$3.92M-2.54190News CoverageRAPPRapport Therapeutics1.3532 of 5 stars$11.37-0.5%$32.67+187.3%-48.3%$417.17MN/A-3.30N/AGap UpORKAOruka Therapeutics2.2118 of 5 stars$11.21+1.2%$40.38+260.2%N/A$414.84MN/A-2.49N/ANews CoveragePRTCPureTech Health2.0613 of 5 stars$17.25+0.6%$45.00+160.9%-22.2%$411.92M$4.83M0.00100Gap Up Related Companies and Tools Related Companies aTyr Pharma Alternatives Kamada Alternatives atai Life Sciences Alternatives Tourmaline Bio Alternatives Mereo BioPharma Group Alternatives REGENXBIO Alternatives Precigen Alternatives Rapport Therapeutics Alternatives Oruka Therapeutics Alternatives PureTech Health Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNLX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Genelux With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNLX Stock Alerts